| Literature DB >> 16846493 |
Isdore C Shamputa1, Levan Jugheli, Nikoloz Sadradze, Eve Willery, Françoise Portaels, Philip Supply, Leen Rigouts.
Abstract
BACKGROUND: Studies on recurrent tuberculosis (TB), TB molecular epidemiology and drug susceptibility testing rely on the analysis of one Mycobacterium tuberculosis isolate from a single sputum sample collected at different disease episodes. This scheme rests on the postulate that a culture of one sputum sample is homogeneous and representative of the total bacillary population in a patient.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16846493 PMCID: PMC1538999 DOI: 10.1186/1465-9921-7-99
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Figure 1Schematic diagram showing the grouping of patients according to culture results and subsequent IS6110-RFLP and MIRU-VNTR typing.
Results of 33 patients with multiple pre-treatment isolates showing variant DNA fingerprinting patterns
| Patient no. | No. of bands different by IS | No. of loci with different/double alleles | Interpretation |
| 1 | >3 | 10 | Mixed infection |
| 2 | >3 | 10 | Mixed infection |
| 3 | >3 | 12 | Mixed infection |
| 4 | >3 | 14 | Mixed infection |
| 5 | >3 | 10 | Mixed infection |
| 6 | >3 | 11 | Mixed infection |
| 7 | >3 | 13 | Mixed infection |
| 8 | >3 | 8 | Mixed infection |
| 9 | >3 | 11 | Mixed infection |
| 10 | >3 | 15 | Mixed infection |
| 11 | >3 | 10 | Mixed infection |
| 12 | >3 | 12 | Mixed infection |
| 13 | >3 | 8 | Mixed infection |
| 14 | >3 | 7 | Mixed infection |
| 15 | >3 | 9 | Mixed infection |
| 16 | >3 | 10 | Mixed infection |
| 17 | >3 | 9 | Mixed infection |
| 18 | >3 | 12 | Mixed infection |
| 19 | 1 | 5 | Mixed infection |
| 29 | 1 | 4 | Mixed infection |
| 30 | 3 | 7 | Mixed infection |
| 31 | 0 | 2 | Mixed infection |
| 32 | 0 | 7 | Mixed infection |
| 33 | 0 | 10 | Mixed infection |
| 22 | 1 | 4 | Mixed infection |
| 24 | 1 | 13 | Mixed infection |
| 20 | 1 | 0 | Identical/subpopulations |
| 21 | 1 | 0 | Identical/subpopulations |
| 23 | 1 | 0 | Identical/subpopulations |
| 25 | 1 | 0 | Identical/subpopulations |
| 26 | 1 | 0 | Identical/subpopulations |
| 27 | 1 | 0 | Identical/subpopulations |
| 28 | 3 | 0 | Identical/subpopulations |
Patients are arranged according to the interpretation
Patient and drug susceptibility results of pre-treatment isolates from patients with variant DNA fingerprinting patterns
| 2 | New case | 23 | a | NT | NT | NT | NT |
| b | S | S | S | S | |||
| 6 | New case | 22 | a + b + c | S | S | S | S |
| 7 | New case | 36 | a + b + c | S | S | S | S |
| 8 | New case | 38 | a + b | S | S | S | S |
| 12 | New case | 41 | a + b + c | S | S | S | S |
| 17 | New case | 57 | a + c | S | S | S | S |
| 18 | New case | 34 | a + c | S | S | S | S |
| 19 | New case | 24 | b + c | S | S | S | S |
| 30 | New case | NA | a + b + c | S | S | S | S |
| 5 | New case | 26 | a + b | R | S | S | S |
| 11 | New case | 29 | a + b | S | S | R | S |
| 10 | New case | 27 | a + b + c | S | S | R | S |
| 24 | New case | 58 | b + c | S | S | R | S |
| 33 | New case | 23 | a + b | S | S | R | S |
| 29 | Return after default | 29 | a + b | S | S | R | S |
| 22 | Previously received non-official TB treatment | 27 | a + b | S | S | R | S |
| 16 | New case | 29 | a + b | R | S | R | S |
| 31 | Relapse case | 38 | a + b | R | R | R | R |
| 3 | New case | 44 | a + b+ c | R | R | R | R |
| 32 | Failure case | 21 | b + c | R | R | R | R |
| 14 | New case | 41 | b | S | S | S | S |
| c | S | S | S | ||||
| 13 | New case | 51 | a | R | S | S | S |
| c | R | S | S | ||||
| 4 | New case | 36 | a | S | S | S | |
| b | S | S | S | ||||
| 1 | Previously received non-official TB treatment | 50 | a | S | S | R | S |
| b | S | R | S | ||||
| c | S | R | S | ||||
| 15 | Return after default | 29 | a | R | S | S | S |
| b | R | S | S | ||||
| c | R | S | S | ||||
| 9 | New case | 24 | a | R | S | R | S |
| c | S | R | S | ||||
| 25 | New case | 25 | b + c | S | S | S | S |
| 20 | Relapse case | 27 | a + b + c | S | S | S | S |
| 21 | New case | 43 | b + c | S | S | R | S |
| 26 | New case | 37 | b + c | S | S | R | S |
| 27 | New case | 27 | a + b | S | S | R | S |
| 28 | New case | 40 | a + b + c | S | S | R | S |
| 23 | New case | 32 | a + b + c | R | S | R | S |
Definitions of abbreviations: INH = isoniazid; RIF = rifampicin; SM = streptomycin; EMB = ethambutol, S = Susceptible; R = Resistant; R? = borderline resistance; NT = not tested; a = first pretreatment sputum; b = second pretreatment sputum; c = third pretreatment sputum; NA = not available.